Despite an expanding therapeutic armamentarium, remission rates in inflammatory bowel disease (IBD) appear to plateau at 30–50% after 1 year of treatment, leading to the concept of a therapeutic ...

UCB agreed to acquire Candid Therapeutics, a privately held clinical-stage biotechnology company focused on autoimmune and inflammatory diseases, for up to $2.2 billion, the companies said Sunday. The ...

UCB UCB0.73%increase; green up pointing triangle said it agreed to buy Candid Therapeutics for up to $2.2 billion, in a deal that seeks to bolster the Belgian pharmaceutical company’s pipeline of ...

UCB researchers at work. UCB has agreed to acquire Candid Therapeutics for up-to-$2.2 billion, the companies said, in a deal designed to expand the buyer’s presence in T-cell engager (TCE) antibodies ...

Transmission electron microscope image of a thin section cut through an area of mammalian lung tissue. The high magnification image shows two mitochondria. People living with thymidine kinase 2 ...

UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merger with Rallybio to challenge Gilead for an emerging opportunity for T-cell engagers (TCEs) ...

Ken Song, Candid Therapeutics' CEO, previously sold radiopharma startup RayzeBio to BMS for $4.1bn. Belgian biotech UCB has made its second acquisition of the year, agreeing a front-loaded takeover of ...

Personalized algorithms may quietly sabotage how people learn, nudging them into narrow tunnels of information even when they start with zero prior knowledge. In the study, participants using ...

Lizzo didn’t sample it, didn’t lip sync it, didn’t drop it in the background of a thirst trap. She remade UCB’s “Sexy Lady.” ...

United Commercial Bank (UCB) is currently running a forensic audit to look into the role played by the previous board of directors and management committee, its new chairman, Sharif Zahir, said in a ...